SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 137 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,763,029 | -28.5% | 1,360,920 | +3.0% | 0.00% | -33.3% |
| Q2 2023 | $27,650,692 | +6.6% | 1,321,103 | +7.6% | 0.00% | 0.0% |
| Q1 2023 | $25,926,940 | +92426.8% | 1,227,601 | +11.5% | 0.00% | -25.0% |
| Q4 2022 | $28,021 | -99.9% | 1,101,029 | +13.7% | 0.00% | 0.0% |
| Q3 2022 | $23,264,000 | +33.2% | 968,129 | +6.6% | 0.00% | +33.3% |
| Q2 2022 | $17,467,000 | +17.5% | 907,856 | +6.1% | 0.00% | +50.0% |
| Q1 2022 | $14,867,000 | -11.2% | 855,415 | +11.9% | 0.00% | 0.0% |
| Q4 2021 | $16,737,000 | +19.5% | 764,627 | +4.3% | 0.00% | 0.0% |
| Q3 2021 | $14,011,000 | +15.4% | 733,220 | +3.7% | 0.00% | 0.0% |
| Q2 2021 | $12,138,000 | -4.2% | 706,942 | +24.7% | 0.00% | 0.0% |
| Q1 2021 | $12,676,000 | +23.1% | 566,923 | +22.4% | 0.00% | 0.0% |
| Q4 2020 | $10,301,000 | +69.4% | 463,176 | +12.4% | 0.00% | +100.0% |
| Q3 2020 | $6,081,000 | -1.0% | 412,013 | -0.6% | 0.00% | 0.0% |
| Q2 2020 | $6,145,000 | +68.1% | 414,690 | +24.4% | 0.00% | 0.0% |
| Q1 2020 | $3,655,000 | -30.6% | 333,258 | -44.5% | 0.00% | 0.0% |
| Q4 2019 | $5,270,000 | +146.5% | 600,402 | +109.8% | 0.00% | – |
| Q3 2019 | $2,138,000 | -14.5% | 286,238 | +6.6% | 0.00% | -100.0% |
| Q2 2019 | $2,500,000 | +141.1% | 268,557 | +35.9% | 0.00% | – |
| Q1 2019 | $1,037,000 | -35.3% | 197,606 | -45.2% | 0.00% | – |
| Q4 2018 | $1,602,000 | +14.3% | 360,398 | +107.8% | 0.00% | – |
| Q3 2018 | $1,401,000 | +18.5% | 173,431 | +3.0% | 0.00% | – |
| Q2 2018 | $1,182,000 | -46.2% | 168,391 | +9.0% | 0.00% | -100.0% |
| Q1 2018 | $2,199,000 | +63.6% | 154,556 | +0.7% | 0.00% | – |
| Q4 2017 | $1,344,000 | -12.0% | 153,483 | +17.4% | 0.00% | -100.0% |
| Q3 2017 | $1,528,000 | -13.2% | 130,680 | +3.7% | 0.00% | 0.0% |
| Q2 2017 | $1,760,000 | +29.7% | 125,999 | +27.3% | 0.00% | 0.0% |
| Q1 2017 | $1,357,000 | +111.4% | 98,962 | +10.5% | 0.00% | – |
| Q4 2016 | $642,000 | -51.3% | 89,552 | +2.9% | 0.00% | -100.0% |
| Q3 2016 | $1,319,000 | +347.1% | 87,035 | +190.3% | 0.00% | – |
| Q2 2016 | $295,000 | – | 29,979 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |